Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342477 | 0.90 | LMNA (0.44) | KCNJ1AKR1C3MEN1KMT2ALMNA | |
| SCHEMBL28524238 | 0.78 | AKR1C3 (0.46) | AKR1C3MEN1KMT2ALMNATSHR | |
| SCHEMBL10959985 | 0.78 | AKR1C3 (0.46) | AKR1C3MEN1KMT2ALMNATSHR | |
| SCHEMBL29151217 | 0.76 | HTT (0.52) | MEN1KMT2ALMNACYP2C19CYP1A2 | |
| SCHEMBL23111943 | 0.75 | KMT2A (0.50) | AKR1C3MEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL29602251 | 0.75 | KMT2A (0.50) | AKR1C3MEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL28611322 | 0.75 | MEN1 (0.47) | AKR1C3MEN1KMT2ALMNATSHR | |
| SCHEMBL7761586 | 0.75 | TSHR (0.49) | KCNJ1AKR1C3MEN1KMT2ALMNA | |
| SCHEMBL28756030 | 0.74 | MEN1 (0.46) | AKR1C3MEN1KMT2ALMNATSHR | |
| SCHEMBL3091161 | 0.73 | TSHR (0.53) | MEN1KMT2ALMNATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2411010-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | KCNJ1 305/4885AKR1C3 1399/4885MEN1 643/4885 |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | KCNJ1 442/4885AKR1C3 451/4885MEN1 1574/4885 |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | KCNJ1 237/4885AKR1C3 1061/4885MEN1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.